The White House is considering adding Bitcoin to the U.S. strategic reserve, with initial efforts focused on properly safeguarding, accounting for, and managing these digital assets. Executive Director Patrick Witt emphasized that the administration is still in the exploratory phase and has not yet decided on how or when to acquire more Bitcoin. This cautious approach highlights the importance of secure custody and accurate accounting before any potential expansion of the reserve. No confirmed purchases or policy changes have been announced at this stage.
The White House's exploration of adding Bitcoin to the U.S. strategic reserve provides context for cryptocurrency market activity. For readers following crypto markets, here is Pluang's snapshot as of Oct 15, 2026 01:31 WIB: out of 50 major cryptocurrencies priced on Pluang, 6 rose and 43 fell today. Notable movers include THETA at Rp3.535 with a 1-day change of -4.15% and 100% buy order activity, XTZ at Rp5.551 down 4.08% with 60% buy orders, and LINK at Rp222.419 down 3.90% with 93% sell orders.
Jefferies has maintained a Buy rating on Big Yellow Group despite recent stock declines, citing the company's strong fundamentals including freehold properties and solid cash flows. Activist investor Ancora, holding over 4% of shares, is pushing Big ...
Fastenal reported strong Q3 2026 earnings, beating analyst expectations with EPS of $0.35 and revenue of $2.46 billion. The company saw a 20% rise in net income to $401.6 million and a 15.5% increase in revenue driven by robust manufacturing demand, ...
Remittix announced the public launch of its RTX token on November 24, 2026, marking the end of its presale phase which raised over $32 million from 40,000 participants. The project is testing its PayFi platform, which enables crypto-to-fiat and fiat-...
The global microbiology testing market is projected to grow rapidly at a compound annual growth rate (CAGR) of approximately 9% from 2026 to 2034, reaching a market size of $13.7 billion by 2034. This growth is driven by the rising prevalence of infe...
H.C. Wainwright raised its price target for Alector from $5.00 to $8.00, maintaining a Buy rating due to progress in its neurodegenerative disease pipeline. Alector develops treatments for Alzheimer's and Parkinson's using its Brain Carrier platform ...
